Novo Nordisk Launches $8.5 B Bid for Metsera, Igniting Pfizer Takeover Duel
Novo Nordisk has made an unsolicited offer to acquire US biotech Metsera, aiming to outbid Pfizer in the competitive obesity-drug market. Novo is offering $56.50 per share in cash plus up to $21.25 in milestone payments, valuing the deal at about $8.5 billion. Metsera’s board has declared Novo’s proposal a “Superior Company Proposal” under its…